Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors

SIMPLE SUMMARY: Recently, patients with high-TMB tumors received agnostic FDA approval to be treated with pembrolizumab. However, some high-TMB patients do not show clinical benefits from this strategy. In this manuscript, we investigated a large cohort of 488 patients with TMB ≥ 10 mut/Mb treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Xavier, Camila B., Lopes, Carlos Diego H., Awni, Beatriz M., Campos, Eduardo F., Alves, João Pedro B., Camargo, Anamaria A., Guardia, Gabriela D. A., Galante, Pedro A. F., Jardim, Denis L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657500/
https://www.ncbi.nlm.nih.gov/pubmed/36358851
http://dx.doi.org/10.3390/cancers14215433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657500/
https://www.ncbi.nlm.nih.gov/pubmed/36358851
http://dx.doi.org/10.3390/cancers14215433

Ejemplares similares